OPKO Health Inc
OPK1.385USD
-0.015-1.07%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.06BCap. mercado
PérdidaP/E TTM
Más Datos de OPKO Health Inc Compañía
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Información de OPKO Health Inc
Símbolo de cotizaciónOPK
Nombre de la empresaOPKO Health Inc
Fecha de salida a bolsaNov 02, 1995
Director ejecutivoDr. Tony F. Cruz, Ph.D.
Número de empleados2997
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 02
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ Global Select Consolidated
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónOPK
Fecha de salida a bolsaNov 02, 1995
Director ejecutivoDr. Tony F. Cruz, Ph.D.
Ejecutivos de OPKO Health Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
114.88M
73.26%
Chile
16.00M
15.83%
Ireland
11.74M
11.61%
Spain
6.72M
6.65%
Mexico
6.30M
6.23%
Otro
-54.55M
-13.59%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.97%
Hsiao (Jane H)
4.32%
Otro
50.53%
Accionistas
Accionistas
Proporción
Frost Gamma Investments Trust
28.70%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.97%
Hsiao (Jane H)
4.32%
Otro
50.53%
Tipos de accionistas
Accionistas
Proporción
Corporation
37.85%
Investment Advisor
12.39%
Individual Investor
10.57%
Hedge Fund
7.62%
Investment Advisor/Hedge Fund
5.83%
Research Firm
1.05%
Bank and Trust
0.16%
Pension Fund
0.12%
Family Office
0.02%
Otro
24.39%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
455
208.86M
27.21%
-55.45M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Frost Gamma Investments Trust
220.16M
27.74%
+360.00K
+0.16%
Sep 30, 2025
Rubric Capital Management LP
47.79M
6.02%
-915.40K
-1.88%
Jun 30, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
The Vanguard Group, Inc.
38.16M
4.81%
+8.74M
+29.70%
Jun 30, 2025
Hsiao (Jane H)
33.13M
4.17%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
28.22M
3.55%
+3.45M
+13.93%
Jun 30, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
10.42M
1.31%
+2.00M
+23.68%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.55%
SPDR S&P Health Care Services ETF
0.49%
VanEck Israel ETF
0.15%
Humankind US Stock ETF
0.11%
iShares U.S. Healthcare Providers ETF
0.11%
Goldman Sachs Innovate Equity ETF
0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.55%
SPDR S&P Health Care Services ETF
Proporción0.49%
VanEck Israel ETF
Proporción0.15%
Humankind US Stock ETF
Proporción0.11%
iShares U.S. Healthcare Providers ETF
Proporción0.11%
Goldman Sachs Innovate Equity ETF
Proporción0.08%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.06%
iShares Biotechnology ETF
Proporción0.05%
iShares Russell 2000 Value ETF
Proporción0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
